Plants are a cost-effective, safe, and efficacious platform for large-scale production of vaccine in emerging economies. Key players in the market are focused on Research & Development (R&D) activities for development of plant-based vaccines for the treatment of infectious diseases. This is owing to the ability of plant-based vaccines to be mass produced, with higher efficiency, while maintaining lower cost compared to conventional vaccines. Plants as a vaccine source have the ability to generate complex recombinant proteins with desired structures, while maintaining biological functions and offering greater immune-specificity. Plants can be used as potential delivery system for oral vaccines.
Market Dynamics
Increasing geriatric population in Europe is another important factor for growth of the plant-based vaccine market in the region. According to the European Centre for Disease Prevention and Control’s (ECDC) - Seasonal influenza 2019-2020, Annual Epidemiological Report, nine countries in Europe reported nearly 10,705 laboratory-confirmed hospitalized influenza cases from 2019-2020 influenza season, among which 87% cases were due to influenza type A viruses.
Moreover, increasing prevalence of infectious diseases is expected to drive growth of the plant-based vaccines market. For instance, according to World Health Organization (WHO) December 2017 estimate, a seasonal influenza may result in 290,000- 650,000 deaths each year owing to respiratory diseases alone.
Higher efficiency of plant-based vaccines over conventional vaccines and R&D activities and clinical trials for the development of plant-based vaccines are some of the factors expected to boost the growth of the market. Plant-based vaccines against HIV have gained significant traction of researchers, since AIDS has evolved as an alarming health problem, which is increasing economic burden of African countries and several emerging economies. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS); in 2017, Eastern Europe, Central Asia, the Middle East and North Africa accounted for 95% of new HIV infections. Easy production, oral administration of plant-based vaccines, and absence of purification needs offer great advantage in designing plant-based viral vaccines.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 37 market data tables and 36 figures on “Global Plant-based Vaccines Market” - Global forecast to 2032
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients